



Local cos can eye patents in US

23 Jul, 2007, 0442 hrs IST, Gireesh Chandra Prasad, TNN

[Print](#) [Save](#) [Email](#) [Write to Editor](#)

NEW DELHI: A Crucial bill making its way through the US Congress is set to give a new inexpensive option for Indian drug makers to attack the patents that give monopoly rights to top-selling MNC brands in the largest pharmaceutical market.

The bill passed by the judiciary committees of the House and the Senate last week, for a sweeping overhaul of the US patent system, allows an interested party to invalidate patents outside a court of law. They could approach the US Patent and Trademark Office (USPTO) for this after the patent is issued.

"The patent reform is beneficial to Indian companies as they are usually not patent holders and are often excluded from the US market by the threat from weak patents," said US-based intellectual property law firm Darby & Darby PC's Washington DC Office managing principal Dr Raj S Dave.

There will be two windows for filing petition for cancellation of a patent. The first is within 12 months of issue or reissue of the patent. The second window is available if the continued existence of patent claim is likely to cause the petitioner significant economic harm and the petitioner has received a notice from the patentee alleging infringement, said Dr Dave in reply to an ET questionnaire. It allows one to challenge a patent anytime during its life at a fraction of the cost of litigation.

"This provision will subject many existing US patents to an immediate threat of invalidation as it makes easier to show the obviousness of the invention. Seeking invalidation of patent is likely to be a part of the patent strategy that Indian generics companies may follow in the US. Companies could either make use of this provision or opt for the existing process of litigation or a mix of both depending on legal advice on a case to case basis," said Indian Pharmaceutical Alliance secretary general DG Shah. Now, requesting marketing approval for a patented drug's generic copy leads to the innovator suing the applicant.

There are some major differences between moving the patent office for revoking a patent and filing for marketing approval and risking litigation. If the patent is invalidated at the patent office, the market for the drug is open to all generics makers unlike in the second case, where the successful generics company gets a six month market monopoly. Since only the first company to successfully file para four application is entitled to the six month market monopoly, companies may not wait for the patent office decision.

Other stories in this section


- [Ipca Labs in talks for in-licensing drugs](#)
- [Local cos can eye patents in US](#)
- [A new sun rises on Shanghai's profit strategy](#)
- [Cipla net down 30% at Rs 120 cr](#)
- [Ranbaxy's Simvastatin to go Down Under by Aug](#)

[More >>](#)

Other News

- [America's loss may be India's gain](#)
- [Investors keep a sharp eye on 'soldiers of fortune'](#)
- [Re rise may hit pay hike for IT staff](#)

Market



Index	Value	Change
SENSEX	15732.20	166.65
NIFTY	4619.35	53.30
DJIA	2687.60	-32.44
NASDAQ	13851.08	-149.33
RS/\$	40.33	0.00

Corporate Announcement

[Corporate events this week](#)

[More >>](#)

ET Debates

- [What does rising Re mean for IT sector?](#)
- [Will new norms make IDRs attractive?](#)
- [Airline mergers bad news for consumers](#)

[More >>](#)

ET Updates Most Read Most Emailed

- [Ruia to fund 'The Elders' group](#) (1650hrs)
- [JNPT shortlists Van Oord for Rs 800-cr dredging project](#) (0440hrs)
- [Godrej acquires Koltaka-based co](#) (1630hrs)
- [Dr Reddys Q1 net profit up 10 pc](#) (1620hrs)

[More >>](#)

REPLAY

Get a free round trip flight for your companion from Cleartrip

When you make a booking at the Oberoi Resorts or Hotel

Click here to [Book Now](#)

* Condition Apply

cleartrip.com
makingtravelsimple

i-Bazaar

Shop

Digital Cameras @ Lowest Prices [Buy Now>](#)

[Better Homes & Gardens](#)

70% off

office s decision.

"The provision has to be used judiciously," says Ranbaxy executive director corporate affairs and global corporate communications Ramesh L Adige. "The documents and arguments a petitioner relies on for invalidation at the patent office cannot be relied upon in a court of law, as the law stands today. Therefore, losing the case at the patent office means the company needs fresh ground to challenge the patent elsewhere," he told ET. He added that the reforms are still some way off as they need to be voted in the full house and senate.

The reforms will give more flexibility and freedom for adopting the appropriate patent challenge strategy on a case to case basis, said Anoop Narayanan of Mumbai-based law firm Majmudar & Co.

[Print](#) [Save](#) [E-Mail](#) [Write to Editor](#)

Bad Response From Server

Bad Response From Server

The Economist + 1 GB Pen Drive 52% off [More >>](#)

Travel

Delhi to Mumbai Rs 925
Hyderabad to B'lore Rs 825
Mumbai to Chennai Rs 600 [More >>](#)

Mobile 8888

[Spiritual mobile wallpapers](#)
[Metro topping music charts](#) [More >>](#)

Related Ads

- Patent Trademark India
- Patent Law Firm in India
- Pharmaceutical Patent
- Sales Patent
- US Patent Litigation



Comments to the Editor

Be the first to write to the Editor.

Write here ...

[Terms & conditions](#)

Name : Location :

Email :